Seqirus (United States)

Recent papers from Seqirus (United States)

1. Clinical and public health economic impact of rapid strain-matched vaccination in influenza pandemic mitigation: A UK-like population dynamic transmission modelHuman Vaccines & Immunotherapeutics · 2026
2. Heterologous prime-boost vaccination against H5 avian influenza: Safety and immunogenicity of a MF59-adjuvanted, cell-culture derived H5N6 vaccineHuman Vaccines & Immunotherapeutics · 2026
3. Adjuvanted and high-dose influenza vaccines had comparable effectiveness against test-confirmed influenza outcomes including hospitalizations in overall and high-risk older adults in the 2022–2023 and 2023–2024 seasonsInternational Journal of Infectious Diseases · 2026
4. Evaluating the cost-effectiveness of adjuvanted influenza vaccine in the older adult population in the NetherlandsHuman Vaccines & Immunotherapeutics · 2026
5. Modern Approaches to the Disclosure of ESG Information in the Corporate Reporting of FMCG-CompaniesAuditor · 2026
6. Using an RNA binding protein to detect mRNA on lipid nanoparticlesScientific Reports · 2026
7. Vaccines as Global Health Security Infrastructure: Insights from a Descriptive Analysis of Vaccines Europe Members’ Clinical PipelinesVaccines · 2026
8. ModiCal: A Targeted Calibration Workflow for Site-Specific m ⁵ C Validation by Nanopore Direct RNA SequencingACS Chemical Biology · 2026
9. Adjuvanted vs High-Dose Influenza Vaccines in Older US AdultsJAMA Network Open · 2026
10. Development of an adjuvanted, higher-dose, cell-based influenza vaccine: combining advanced technologies to improve vaccine effectiveness.2026
11. Potential to Avert Additional Influenza Burden in the United States with Use of Adjuvanted vs. Standard Influenza Vaccines in Individuals 50–64 Years of AgeVaccines · 2026
12. Plasma Proteomics Across Three Generations of Mass Spectrometry Instruments: Lessons for Biofluid Method OptimisationPROTEOMICS · 2026
13. Cost-effectiveness of vaccination of older adults with an MF59®-adjuvanted quadrivalent influenza vaccine compared to standard-dose and high-dose vaccines in South Korea and TaiwanVaccine · 2026
14. MF59-adjuvanted A/Astrakhan influenza vaccine induces cross-neutralizing H5N1 antibodies in ferrets against circulating clade 2.3.4.4b virusesnpj Vaccines · 2026
15. Historic 1994 influenza vaccine cohorts define breadth of antibody and B cell responses toward future influenza A and B virusesScience Translational Medicine · 2026
16. Immunogenicity and safety of higher-dose cell-based adjuvanted quadrivalent influenza vaccines: Combined results of randomised, controlled dose-finding and dose-confirmation studiesVaccine · 2026
17. Maximizing public health benefits: Policy perspectives on coverage and cell-based influenza vaccines in the USHuman Vaccines & Immunotherapeutics · 2026
18. The Road to Readiness: Commentary on the Journey of a Zoonotic H5 Influenza Vaccine Strain UpdateVaccines · 2026
19. P-1473. Estimated Relative Effectiveness and Public Health Impact of Cell-Based Versus Egg-Based Influenza Vaccines During the 2023–2024 Season in the United StatesOpen Forum Infectious Diseases · 2026
20. P-1476. Safety of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-Adjuvanted Cell Culture-derived Influenza Vaccine in Healthy Subjects ≥18 Years of AgeOpen Forum Infectious Diseases · 2026